Phathom Pharmaceuticals, Inc.
PHATDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How PHAT's past catalysts played out
Amoxicillin
Helicobacter Pylori Infection
Lansoprazole
Erosive Esophagitis
Vonoprazan
Non-Erosive Gastro-Esophageal Reflux Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Amoxicillin | Phase 3 | Helicobacter Pylori Infection | - | - |
Lansoprazole | Phase 3 | Erosive Esophagitis | - | - |
Vonoprazan | Phase 3 | Non-Erosive Gastro-Esophageal Reflux Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Phathom Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Phathom Pharmaceuticals, Inc.'s (PHAT) pipeline across Phase 3. Its lead program is Amoxicillin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Phathom Pharmaceuticals, Inc.'s next FDA catalyst?→
Phathom Pharmaceuticals, Inc.'s (PHAT) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHAT biotech catalysts?→
Add PHAT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Phathom Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.